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VaccineAbstract Epidemiological evidence suggests a link between mercury (Hg) exposure
from Thimerosal-containing vaccines and specific delays in development. A
hypothesis-testing longitudinal cohort study (n = 49,835) using medical records in
the Vaccine Safety Datalink (VSD) was undertaken to evaluate the relationship
between exposure to Hg from Thimerosal-containing hepatitis B vaccines (T-HBVs)
administered at specific intervals in the first 6 months of life and specific delays
in development [International Classification of Disease, 9th revision (ICD-9):
315.xx] among children born between 1991 and 1994 and continuously enrolled from
birth for at least 5.81 years. Infants receiving increased Hg doses from T-HBVs
administered within the first month, the first 2 months, and the first 6 months of life
were significantly more likely to be diagnosed with specific delays in development
than infants receiving no Hg doses from T-HBVs. During the decade in which
T-HBVs were routinely recommended and administered to US infants (1991–2001),
106 D.A. Geier et al.an estimated 0.5–1 million additional US children were diagnosed with specific
delays in development as a consequence of 25 lg or 37.5 lg organic Hg from
T-HBVs administered within the first 6 months of life. The resulting lifetime costs
to the United States may exceed $1 trillion.
ª 2015 The Authors. Published by Elsevier Ltd. on behalf of Ministry of Health, Saudi
Arabia. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Thimerosal is a mercury (Hg)-containing compound
(49.55% Hg weight) used by pharmaceutical compa-
nies, and was developed in 1927. It has been added
to a range of pharmaceutical products as an antimi-
crobial [1]. Following administration of Thimerosal-
containing vaccines, Thimerosal rapidly dissociates
into ethyl-Hg [2] which rapidly binds onto blood
constituents [3] and is transported to many tissues
in the body, including the brain [4]. Of particular
concern, ethyl-Hg is actively transported across
neuronal membranes [5], such as by the L-type neu-
tral amino acid carrier transport system [6].
During the 1990s, US infants were exposed to sig-
nificant amounts of organic Hg from Thimerosal-
containing hepatitis B vaccine (T-HBV), diph
theria–tetanus–pertussis (DTP), and Haemophilus
influenzae type B (Hib) vaccines administered at
periodic intervals within the first 6 months of life.
Typically, nominal concentrations of Thimerosal
present in infant vaccines ranged from 0.005% to
0.01% (12.5 lg Hg/0.5 mL vaccine dose or 25 lg
Hg/0.5 mL vaccine dose) [4]. Infants may have been
exposed to bolus doses of organic Hg nominally
ranging from 12.5 lg Hg to 62.5 lg organic Hg, col-
lectively totaling up to nominally 200 lg organic Hg
from Thimerosal-containing childhood vaccines
during the first 6 months of life, representing >50%
of all Hg exposure when considering environmental
sources of Hg [4]. This dosing pattern continues
unabated in many developing nations to the present
day, and many US children continue to receive sig-
nificant doses of organic Hg from the routinely rec-
ommended administration of Thimerosal-contai
ning influenza vaccines (where >50% of all doses
of influenza vaccine continue to contain 0.01%
Thimerosal) given to pregnant women, infants,
and young children [4].
In 2003, some of the co-authors of this article
proposed that the hypothesis that exposure to
Thimerosal-containing vaccines was associated
with specific delays in development rested on indi-
rect and incomplete information, primarily from
analogies with methyl-Hg and levels of maximum
Hg exposure from vaccines given to children [7].It was suggested that the hypothesis was biologi-
cally plausible, but that the possible relationship
bet ween Thimerosal-containing vaccines and
specific delays in development was unproven at
that time. As of 2003, no peer-reviewed epidemio-
logical studies in the scientific literature had
evaluated the potential association between
Thimerosal-cont aining vaccines and specific delays
in development. Our study was the first epidemio-
logical study to report a significant association
between the administration of tens of millions of
doses of Thimerosal-containing diphtheria–teta
nus–acellular-pertussis (DTaP) vaccines to US
children and specific delays in development based
upon assessment of the Vaccine Adverse Event
Reporting System (VAERS) database.
Subsequent studies in the United States have
revealed significant associations between specific
delays in development and administration of
Thimerosal-containing vaccines to infants in the
VAERS [7,8], the Vaccine Safety Datalink (VSD)
[9,10], and the National Health and Nutrition
Examination Survey (NHANES) [11] databases.
The purpose of the present study was to extend
previous research by conducting a longitudinal
cohort study of prospectively collected automated
medical records in the VSD database to further
evaluate the relationship between organic Hg
exposure from T-HBVs administered in the first
6 months of life, and the risk of a child being diag-
nosed with specific delays in development (or
learning disability).
2. Methods
The study protocol was approved by the US Centers
for Disease Control and Prevention (CDC), the
Institutional Review Board of Kaiser Permanente
North-West (KPNW; ID: NW-05MGeie-01), and the
Institutional Review Board of Kaiser Permanente
Northern California (KPNC; ID: CN-03MGeie-01-H).
Data were analyzed at the secure Research Data
Center of the National Center for Health Statistics
in Hyattsville, MD, USA. The views expressed in this
study do not necessarily reflect those of the CDC or
those of Kaiser Permanente.
Thimerosal 107The VSD project was created in 1991 by the
National Immunization Program of the CDC, and
VSD data collection and study methods have been
previously described [12–16]. The project links
medical event information, specific vaccine his-
tory, and selected demographic information from
the computerized databases of several health
maintenance organizations (HMOs).
2.1. Study participants
An overall cohort of over 1.9 million children
enrolled in the VSD project (updated through the
end of 2000) from KPNW, Kaiser Permanente
Colorado, and KPNC was examined using SAS soft-
ware (SAS Institute Inc., 100 SAS Campus Drive,
Cary, NC 27513-2414, USA). Among the overall
cohort of children, a subset of children with non-
missing date of birth and nonmissing sex (who were
HMO-enrolled from their date of birth) was further
examined.
The outcome files (inpatient and outpatient diag-
noses) from this subset of children were then
reviewed to find the first instance of International
Classification of Disease, 9th revision (ICD-9)-
diagnosed specific delays in development, includ-
ing: reading disorder, unspecified (315.00), alexia
(315.01), developmental dyslexia (315.02), specific
spelling difficulty (315.09), dyscalculia (315.1), dis-
order of written expression (315.2), expressive lan-
guage disorder (315.31), mixed receptive–exp
ressive language disorder (315.32), speech and lan-
guage developmental delay due to hearing loss (31
5.34), developmental articulation disorder (31
5.39), developmental coordination disorder
(315.4), mixed development disorder (315.5), other
specified delays in development (315.8), and
unspecified delay in development (315.9). If there
were multiple instances of the same diagnosis in a
child, only the first instance was counted.
The records of the children diagnosed with speci-
fic delays in development were then reviewed to
determine the mean age of initial diagnosis
(2.63 years of age) and the standard deviation age
of mean initial diagnosis (1.59 years of age). Then,
using this information, we required that every
member of the cohort assembled for our study
had to be continuously enrolled from birth for at
least 5.81 years (mean age of initial diagno-
sis + 2 · standard deviation of initial diagnosis). As
a result, a cohort of 49,835 children (males = 25,624
and females = 24,210; male to female ratio = 1.06),
born between 1991 and 1994, was examined in the
present study.2.2. Hepatitis B vaccine exposure
The vaccine file for the cohort was then reviewed
to determine the exact dates of hepatitis B vaccine
administration. Those members of the cohort
receiving no doses of hepatitis B vaccine were also
included in the present study. Overall among mem-
bers of the cohort, Hg exposure was assigned as
12.5 lg organic Hg/dose for those receiving a pedi-
atric hepatitis B vaccine or 0 lg organic Hg/dose
for those receiving either combined Haemophilus
influenzae type B (Hib)-hepatitis B vaccine or nei-
ther of the aforementioned vaccines (0 lg organic
Hg/dose from T-HBV). In addition, to allow for a
potential association between exposure and out-
come, individuals diagnosed with specific delays
in development before administration of the vacci-
nes examined in the present study were excluded.
2.3. Statistical analyses
In all statistical analyses, the StatsDirect statistical
software (Version 2.8.0, StatsDirect Ltd., 9
Bonville Chase, Altrincham, Cheshire WA 14 4QA,
UK) was utilized, and a two-sided p value < 0.05
was considered statistically significant.
In the first set of experiments, the Fishers exact
test statistic was utilized to examine the relation-
ship between increasing amounts of organic Hg
exposure from T-HBV administration and the fre-
quency of diagnosed specific delays in develop-
ment. In the first experimental group (Experiment
I), the data were examined to determine the fre-
quency of diagnosed specific delays in development
among the cohort of children exposed to 12.5 lg
organic Hg from T-HBV administered in the first
month of life, in comparison with the frequency
of diagnosed specific delays in development among
the cohort of children exposed to 0 lg organic Hg
from T-HBV administered in the first month of life.
In the second experimental group (Experiment II),
the data were examined to determine the fre-
quency of diagnosed specific delays in development
among the cohort of children exposed to 25 lg
organic Hg from T-HBV administered in the first
2 months of life, in comparison with the frequency
of diagnosed specific delays in development among
the cohort of children exposed to 0 lg organic Hg
from T-HBV administered in the first 2 months of
life. In the third experimental group (Experiment
III), the data were examined to determine the fre-
quency of diagnosed specific delays in development
among the cohort of children exposed to 37.5 lg
organic Hg from T-HBV administered in the first
Table 1 A summary of the frequency of diagnosed specific delays in development in comparison with organic mercury exposure from Thimerosal-containing hepatitis B
vaccine administration within the Vaccine Safety Datalink (VSD) database.
Group examined Number diagnosed with
specific delays in
development (%)
Number of individuals
in the cohort
Relative
risk (95% CI)
Attributable
risk % (95% CI)
Population attributable risk % (95% CI)
Experiment I
12.5 lg Organic mercury
within the first mo
828 (4.25) 18,637 1.220* (1.117–1.332) 0.767 (0.420–1.14) 7.64 (4.2–11.08)
0 lg Organic mercury
within the first mo
1127 (3.49) 31,198
Experiment II
25 lg Organic mercury
within the first 2 mo
829 (4.25) 18,660 1.214* (1.112–1.327) 0.751 (0.403–1.10) 7.57 (4.072–11.07)
0 lg Organic mercury
within first 2 mo
1105 (3.50) 30,444
Experiment III
37.5 lg Organic mercury
within the first 6 mo
641 (4.46) 13,725 2.667* (1.866–3.812) 2.89 (2.11–3.46) 59.62 (45.87–73.38)
0 lg Organic mercury
within the first 6 mo
31 (1.67) 1822
CI = confidence interval.
* p < 0.001.
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Table 2 A summary among males of the frequency of diagnosed specific delays in development in comparison with organic mercury exposure from Thimerosal-containing
hepatitis B vaccine administration within the Vaccine Safety Datalink (VSD) database.
Group examined Number of males diagnosed
with specific delays in
development (%)
Number of males
in the cohort
Relative
risk (95% CI)
Attributable
risk % (95% CI)
Population attributable risk % (95% CI)
Experiment IV
12.5 lg Organic mercury
within the first mo
567 (5.62) 9514 1.231* (1.108–1.369) 1.057 (0.508–1.61) 7.965 (3.846–12.08)
0 lg Organic mercury
within the first mo
771 (4.57) 16,110
Experiment V
25 lg Organic mercury
within the first 2 mo
568 (5.63) 9525 1.223* (1.1–1.359) 1.025 (0.4727–1.58) 7.798 (3.614–11.98)
0 lg Organic mercury
within the first 2 mo
758 (4.60) 15,709
Experiment VI
37.5 lg Organic mercury
within the first 6 mo
443 (6.00) 6946 3.148* (1.974–5.018) 4.091 (3.065–5.117) 65.57 (50.13–81)
0 lg Organic mercury
within the first 6 mo
18 (1.90) 927
CI = confidence interval.
* p < 0.001.
T
h
im
e
ro
sal
109
Table 3 A summary among females of the frequency of diagnosed specific delays in development in comparison with organic mercury exposure from Thimerosal-containing
hepatitis B vaccine administration within the Vaccine Safety Datalink (VSD) database.
Group examined Number of females diagnosed
with specific delays in
development (%)
Number of females
in the cohort
Relative
risk (95% CI)
Attributable
risk % (95% CI)
Population attributable
risk % (95% CI)
Experiment VII
12.5 lg Organic mercury
within the first mo
261 (2.78) 9122 1.207* (1.031–1.413) 0.4765 (0.0682–0.885) 7.247 (1.061–13.43)
0 lg Organic mercury
within the first mo
356 (2.31) 15,088
Experiment VIII
25 lg Organic mercury
within the first 2 mo
261 (2.78) 9134 1.207* (1.03–1.415) 0.4773 (0.0678–0.887) 7.376 (1.073–13.68)
0 lg Organic mercury
within the first 2 mo
347 (2.30) 14,735
Experiment IX
37.5 lg Organic mercury
within the first 6 mo
198 (2.84) 6779 1.982* (1.136–3.459) 1.406 (0.541–2.271) 46.5 (18.54–74.46)
0 lg Organic mercury
within the first 6 mo
13 (1.43) 895
CI = confidence interval.
* p < 0.05.
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Table 4 A summary of discrete risk ratio estimates for diagnosed specific delays in development with increasing exposure
to organic mercury (Hg) from Thimerosal-containing hepatitis B vaccine administration within the first 6 months of life.
Exposure Number diagnosed
with specific delays
in development (%)
Number of individuals
in the cohort
Outcome measurement
0 lg Organic Hg (reference dose) 31 (1.701) 1822
12.5 lg Organic Hg 21 (2.873) 731
Relative risk (95% CI) 1.669 (0.971–2.864)
p 0.096
Attributable risk (95% CI) 0.0112 (0.000606–0.0264)
Population attributable risk % (95% CI) 16.191 (2.355–34.737)
25 lg Organic Hg 1262 (3.761) 33,557
Relative risk (95% CI) 2.166 (1.526–3.0814)
p <0.001
Attributable risk (95% CI) 0.0195 (0.0124–0.0249)
Population attributable risk % (95% CI) 52.551 (36.192–68.910)
37.5 lg Organic Hg 641 (4.670) 13,725
Relative risk (95% CI) 2.667 (1.872–3.808)
p <0.001
Attributable risk (95% CI) 0.0279 (0.0203–0.0340)
Population attributable risk % (95% CI) 59.622 (45.865–73.379)
CI = confidence interval.
Thimerosal 1116 months of life, in comparison with the frequency
of diagnosed specific delays in development among
the cohort of children exposed to 0 lg organic Hg
from T-HBV administered in the first 6 months
of life. The aforementioned experiments were
repeated by splitting the data so that male cohorts
(Experiments IV–VI) and female cohorts
(Experiments VII–IX) were analyzed separately.
The overall null hypotheses for each of these
experimental groups were that there would be no
difference in the frequency of diagnosed specific
delays in development regardless of exposure to
organic Hg doses from T-HBVs.
The second set of experiments examined the
potential dose–response relationship between
increasing amounts of organic Hg exposure from
T-HBV administration and the frequency of diag-
nosed specific delays in development utilizing the
linear regression and Fishers exact statistical
tests. The linear regression test was employed to
compare the frequency of diagnosed specific delays
in development/lg organic Hg exposure from T-
HBVs administered within the first 6 months of life.
Additionally, the Fishers exact statistical test was
used to determine the discrete relative risks for
the frequency of diagnosed specific delays in devel-
opment in the cohorts receiving exposure to
12.5 lg organic Hg, 25 lg organic Hg, or 37.5 lg
organic Hg from T-HBV doses, in comparison with
the cohort receiving 0 lg organic Hg fromThimerosal-free hepatitis B vaccine doses and/or
no hepatitis B vaccinations within the first
6 months of life. The overall null hypotheses for
each of these comparisons were that there would
be no difference in the frequency of diagnosed
specific delays in development regardless of expo-
sure to organic Hg from Thimerosal-containing hep-
atitis vaccines.
3. Results
Table 1 displays the frequency of diagnosed specific
delays in development in relation to exposure to
organic Hg from T-HBVs administered at specific
intervals within the first 6 months of life. It was
observed in Experiment I that infants receiving
12.5 lg organic Hg from T-HBVs (4.25% diagnosed
with specific delays in development) in comparison
with infants receiving 0 lg organic Hg from T-HBVs
(3.49% diagnosed with specific delays in develop-
ment) within the first month of life were signifi-
cantly more likely to have received a specific
delays in development diagnosis (relative
risk = 1.220, p < 0.0001). In Experiment II, it was
found that infants receiving 25 lg organic Hg from
T-HBVs (4.25% diagnosed with specific delays in
development) in comparison with infants receiving
0 lg organic Hg from T-HBVs (3.50% diagnosed with
specific delays in development) within the first
2 months of life were significantly more likely to
Fig. 1 A summary of the percent of children diagnosed
with specific delays in development in comparison with
the dose of organic Hg received from Thimerosal-
containing hepatitis B vaccines administered within the
first 6 months of life. The following equation explains the
distribution of the data using the linear regression test:
percent of children diagnosed with specific delays
in development = (0.0784 · lg organic Hg) + 1.782
(p = 0.0023, 95% confidence interval of slope
value = 0.0623–0.0944, r = 0.998, 95% confidence inter-
val of r = 0.892–0.999, r2 = 0.995).
112 D.A. Geier et al.have received a specific delays in development diag-
nosis (relative risk = 1.214, p < 0.0001). Finally, in
Experiment III, it was revealed that infants receiving
37.5 lg organic Hg from T-HBVs (4.46% diagnosed
with specific delays in development), in comparison
with 0 lg organic Hg from T-HBVs (1.67% diagnosed
with specific delays in development) were signifi-
cantly more likely to have received a specific delays
in development diagnosis (relative risk = 2.667,
p < 0.0001). Table 2 (Experiments IV–VI) and
Table 3 (Experiments VII–IX) show similar patterns
of increased relative risk when the data were sepa-
rated by the sex of the vaccine recipients. The attri-
butable risk percent was significantly increased
among boys receiving 37.5 lg organic Hg from T-
HBVs in comparison with 0 lg organic Hg from T-
HBVs within the first 6 months of life (attributable
risk percent = 4.091%, 95% confidence inter-
val = 3.065–5.117) versus girls receiving 37.5 lg
organic Hg from T-HBVs in comparison with 0 lg
organic Hg from T-HBVs within the first 6 months
of life (attributable risk percent = 1.406%, 95% con-
fidence interval = 0.541–2.271).
Table 4 displays the relative risk estimates for
increasing doses of organic Hg exposure from T-
HBVs administered within the first 6 months of life.
It was observed that the cohort of infants receiving
12.5 lg organic Hg from T-HBVs (2.873% diagnosed
with specific delays in development), in compar-
ison with 0 lg organic Hg from T-HBVs (1.701%
diagnosed with specific delays in development)
within the first 6 months of life werenonsignificantly more likely to be diagnosed with
specific delays in development (relative
risk = 1.669, p = 0.0958). It was found that the
cohort of infants receiving 25 lg organic Hg from
T-HBVs (3.761% diagnosed with specific delays in
development), in comparison with 0 lg organic Hg
from T-HBVs within the first 6 months of life, were
significantly more likely to be diagnosed with speci-
fic delays in development (relative risk = 2.166,
p < 0.0001). It was determined that the cohort of
infants receiving 37.5 lg organic Hg from T-HBVs
(4.670% diagnosed with specific delays in develop-
ment) within the first 6 months of life, in compar-
ison with 0 lg organic Hg from T-HBVs within the
first 6 months of life, were significantly more likely
to be diagnosed with specific delays in develop-
ment (relative risk = 2.667, p < 0.0001).
In addition, the linear regression test was used
to compare the frequency of diagnosed specific
delays in development/lg organic Hg exposure
from T-HBVs administered within the first 6 months
of life; it revealed, as shown in Fig. 1, a signifi-
cantly positive dose-dependent correlation
between increasing organic Hg exposure from
T-HBVs and an increasing incidence of diagnosed
specific delays in development. The following
equation explains the distribution of the data
using the linear regression test: percent of
children diagnosed with specific delays in
development = (0.0784 · lg organic Hg) + 1.782
(p = 0.0023, 95% confidence interval of slope
value = 0.0623–0.0944, r = 0.998, 95% confidence
interval of r = 0.892–0.999, r2 = 0.995).4. Discussion
The results of the present study confirm and extend
previous epidemiological studies finding a signifi-
cant relationship between exposure to
Thimerosal-containing childhood vaccines and an
increased risk of specific delays in development.
It was observed, in the overall cohort and the
cohorts separated by sex, that infants who
received increased organic Hg from T-HBVs, in
comparison with infants who received no organic
Hg from T-HBV within the first month of life, the
first 2 months of life, and the first 6 months of life,
were significantly more likely to subsequently be
diagnosed with specific delays in development.
Further, it was observed that there was a signifi-
cant dose-dependent relationship between increas-
ing doses of organic Hg from T-HBVs administered
within the first 6 months of life and the eventual
risk of a child being diagnosed with specific delays
in development.
Table 5 A summary of the estimated number of US children born between 1991 and 2001 (n = 43,597,291) and
diagnosed with specific delays in development attributable to receipt of 25 lg organic mercury (Hg) or 37.5 lg
organic Hg from Thimerosal-containing hepatitis B vaccines administered within the first 6 months of life.
Estimated exposure
percentage (%)
Estimated number
of children exposed
Estimated number
of children diagnosed
with specific delays
in development
95 41,597,291 913,518
85 37,218,629 817,358
75 32,839,966 721,198
50 21,893,311 480,799
The bolded-italicized text is the estimated percentage of children receiving 25 lg organic Hg or 37.5 lg organic Hg from
Thimerosal-containing hepatitis B vaccines administered within the first 6 months of life based upon the present analysis of
the Vaccine Safety Datalink (VSD) database [(33,557 + 13,725)/(1822 + 731 + 33,557 + 13,725) · 100 = 95%].
Thimerosal 113In further considering the implications of the
present study regarding US children, it is important
to note that in 1991, the Advisory Committee on
Immunization Practices recommended that infants
should receive their hepatitis B vaccine doses as
follows: first dose between birth and 2 months of
age, second dose between 1 month of age and
4 months of age, and third dose between 6 months
of age and 18 months of age [17]. Subsequently,
from 1991 through 2001, most doses of hepatitis
B vaccine routinely administered to US infants con-
tained 12.5 lg organic Hg/dose [18,19].
The results of the present study reveal that a
cohort of children receiving 25 lg organic Hg from
T-HBVs or 37.5 lg organic Hg from T-HBVs within
the first 6 months of life was significantly more
likely to be diagnosed with specific delays in devel-
opment than a cohort of children receiving 0 lg
organic Hg from T-HBVs administered within the
first 6 months of life (relative risk = 2.31, 95%
relative risk confidence interval = 1.632–3.285,
p < 0.0001, attributable risk = 0.02196, 95% attribu-
table risk confidence interval = 0.0149–0.0272).
Then, utilizing the yearly live birth estimates of
the CDC [20] to estimate the size of the US birth
cohort between 1991 and 2001, along with the
aforementioned calculation of the risk posed by
receipt of 25 lg organic Hg from T-HBVs or
37.5 lg organic Hg from T-HBVs within the first
6 months of life, in comparison with 0 lg organic
Hg from T-HBVs administered within the first
6 months of life, it was possible to estimate the
attributable number of children diagnosed with
specific delays as a result or organic Hg exposure
from Thimerosal-containing vaccines. Table 5 esti-
mates the number of children impacted based upon
different exposure estimates in the US infant pop-
ulation to T-HBVs. It was estimated, utilizing the
calculated exposure percentage derived from our
analysis of the VSD (95% estimated exposure)database, that 913,518 children born between
1991 and 2001, were diagnosed with specific delays
in development as a consequence of receipt of
25 lg organic Hg from T-HBVs or 37.5 lg organic
Hg from T-HBVs administered within the first
6 months of life. It was estimated, utilizing a much
more conservative estimated exposure percentage
(50% estimated exposure), that 480,799 children
born between 1991 and 2001, were diagnosed with
specific delays in development as a consequence of
receipt of 25 lg organic Hg from T-HBVs or 37.5 lg
organic Hg from T-HBVs administered within the
first 6 months of life. It is important to note from
the data presented in Fig. 1 of our study that while
organic Hg exposure from T-HBVs administered
within the first 6 months of life significantly con-
tributed to an increased number of children being
diagnosed with specific delays in development,
such exposure was not the sole cause of this diag-
nosis (i.e., 1.701% of children were diagnosed with
specific delays in development in the absence of
any organic Hg exposure from T-HBVs administered
within the first 6 months of life).
The long-term consequences of such a large
number of Americans being diagnosed with specific
delays in development from the administration of
T-HBVs are very serious. For example, investigators
reported that individuals diagnosed with learning
disabilities are more prone than the rest of the pop-
ulation to chronic health problems, including epi-
lepsy, dementia, hepatitis, peptic ulcer, dysph
agia, and problems related to sensory impairment,
as well as more likely to suffer more from
age-related diseases such as stroke, cardiovascular
disease, and malignancy [21]. A recent study
estimated that the simple incremental cost of a
learning disability from birth to retirement is
$1.982 million/person with a learning disability
[22]. It is important to consider that many individu-
als diagnosed with learning disabilities have a wide
114 D.A. Geier et al.range of severities, from mild to profound, but the
lifetime incremental cost of a learning disability
estimate utilized in the present study is compatible
with those reported for other developmental dis-
abilities, with a spectrum of severity such as autism
spectrum disorder [23] or attention-deficit/hyperac
tivity disorder [24]. Therefore, utilizing the range
of estimated attributable number of children diag-
nosed with specific delays in development from
receipt of 25 lg organic Hg from T-HBVs or 37.5 lg
organic Hg from T-HBVs administered within the
first 6 months of life, the lifetime cost estimates
to the United States would range from
$952,943,618,000 (50% estimated exposure) to
$1,810,592,676,000 (95% estimated exposure). It
is also important to note that when considering
our cost estimates, the present study did not con-
sider other potential confounding factors that may
have impacted our calculations.
Many recent studies support the biologically
plausible role of organic Hg exposure from
Thimerosal-containing vaccines in the pathogenesis
of specific delays in development [25]. For exam-
ple, administration of Thimerosal mimicking the
US early childhood vaccination schedule of the
1990s to infant monkeys, resulted in significant
and persistent levels of Hg in the brain [26].
Ethyl-Hg is able to enter into the brain and remain
as ethyl-Hg, but it can also become and persist as
methyl-Hg or inorganic Hg [27,28]. Once in the
brain, Hg has many adverse effects [29]. In addi-
tion, studies have revealed that administration of
Thimerosal mimicking the US early childhood vacci-
nation schedule of the 1990s yielded significant
pathology or clinical symptoms in mice [30], rats
[31–33], hamsters [34], and monkeys [35] that
are consistent with those observed in children diag-
nosed with specific delays in development.
In addition, one of the main effects of Hg in the
brain is axonal degeneration, particularly of large
caliber axons which tend to be long-range axons
interconnecting distant parts of the brain [29].
This loss of long-range axons can result in a reduc-
tion of long-range connectivity. Long-range con-
nectivity is particularly important in many
processes in the brain, such as reading, hearing,
coordination, and speech/language [36–41].
Research shows that abnormalities in the long-
range neural tracts associated with these processes
can result in specific delays in development. For
example, investigators showed that the growth
pattern of long-range connections in the brain pre-
dicts how a childs reading skills will develop [40].
Those investigators stated that literacy requires
the integration of activity in brain areas involvedin vision, hearing, and language and, because these
areas are distributed throughout the brain, it
requires more speed-efficient long-range neural
networks to bring about efficient communication
overall between these regions. Investigators have
also found lack of axonal integrity in the long-
range axons of the arcuate fasciculus in children
with delayed speech development [41]. In addition
to Hg causing axonal degeneration, particularly of
these critically important long-range axons that
would require axon guidance, studies have shown
that Hg also inhibits axon guidance [42]. Finally,
studies revealed Hg (and specifically Thimerosal)
disrupts neuronal cell maturation [42,43], which is
another issue noted in children with reading and
speech/language delay [41].
As discussed previously, the results observed in
the present study are consistent with and extend
previous studies conducted in the VAERS [7,8],
VSD [9,10], and NHANES [11] databases, showing
a significant association between organic Hg expo-
sure from Thimerosal-containing childhood vacci-
nes and specific delays in development.
In contrast, the results of the present study differ
from several other studies that failed to find a con-
sistent significant relationship between specific
delays in development and organic Hg exposure
from Thimerosal-containing childhood vaccines
[44,45]. A recent review has critically examined
many of these studies, and found that their results
are uninterpretable [46].
For example, some of these studies examined
cohorts with significantly different childhood vac-
cination schedules and with different diagnostic
criteria for outcomes than those used in the
United States. As another example, these other
studies employed different epidemiological meth-
ods, especially with respect to the issue of a suffi-
cient follow-up period for individuals in the cohorts
examined. The method used to measure how a
follow-up period is determined for individuals is a
critical issue in all studies examining the relation-
ship between exposures and the subsequent risk
of the diagnosis of specific delays in development.
This is the case because the risk of an individual
being diagnosed with specific delays in develop-
ment is not uniform throughout his/her lifetime.
Therefore, any follow-up method that fails to
appropriately consider the lag-time between birth
and the individuals age of an initial diagnosis for
specific delays in development, will likely not be
able to observe the true relationship between
exposure to Hg through vaccination and the subse-
quent risk of a specific delays in development
diagnosis.
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A strength of the present study was its examination
of a cohort of children from the VSD database. The
VSD database observations were made based upon
retrospective assessment of prospectively col-
lected medical records of patients enrolled in var-
ious HMOs. All members of the cohort examined
had to be enrolled from birth and were required
to be continuously enrolled for a sufficient time
to ensure that there was a very small chance that,
during additional follow up, any additional mem-
bers of the cohort would be medically diagnosed
with specific delays in development. As a result,
any factors associated with enrollment (i.e.,
adjustment for potential independent variables
were not necessary because enrollment was from
birth) or healthcare-seeking behavior (i.e., adjust-
ment for potential access/availability of health-
care was continuous among all members of the
cohort) were minimized. In addition, members of
the cohort diagnosed with specific delays in devel-
opment were specifically evaluated to ensure that
only those cases diagnosed with specific delays in
development following vaccine administration
were considered in the present analyses.
Another strength of the present study was that it
mathematically ensured that all the cohorts exam-
ined in the VSD had adequate lengths of follow-up
time. Specifically, the outcome files (inpatient
and outpatient diagnoses) were examined to deter-
mine the age when children continuously enrolled
in the VSD from birth were first diagnosed with
specific delays in development. The observed mean
age of initial diagnosis was 2.63 years of age, with a
standard deviation of initial diagnosis age of
1.59 years. Then, using this information, every
member of the cohort assembled for our study
was required to have been continuously enrolled
from birth for at least 5.81 years (mean age of
initial diagnosis + 2 · standard deviation of initial
diagnosis). Given the available review period
(1991 through 2000) in the VSD, all children in the
cohorts examined were born between 1991 and
1994. Based on the data for age of initial diagnosis
for the specific delays in development studied, this
was a sufficient period to ensure that, with further
follow-up, very few children would receive a speci-
fic delays in development diagnosis presuming a
normal distribution of data, and there is mathe-
matically <2.5% chance of these individuals being
diagnosed with specific delays in development with
additional follow-up time beyond 5.81 years.
Another strength of the present study was that
the VSD data were collected independently of thestudy design. The VSD data records analyzed were
collected as part of the routine healthcare individ-
uals received through their participation with their
respective Kaiser health plans, and as such, the
healthcare providers were not able to anticipate
a potential association between vaccine exposures
and health outcomes.
However, the results of the present study may
have a number of potential limitations. It is possi-
ble that the results observed may have occurred
from unknown biases or confounders present in
the datasets examined. This seems unlikely
because other control outcomes (i.e., outcomes
that are not biologically plausibly linked to postna-
tal organic Hg exposure from Thimerosal-
containing vaccines) were previously extensively
examined in the VSD database, and no similar pat-
terns of significant associations were observed for
those outcomes.
Another potential limitation of the present study
is that the results observed for specific delays in
development may be the result of statistical
chance. However, such a possibility would be unli-
kely given the limited number of statistical tests
performed, the highly significant results observed,
and the consistency in the direction and magnitude
of the results observed.
Still, other potential limitations of the present
study include the possibilities that some of the
individuals in the cohorts examined in the VSD
database may have had more subtle neurological
dysfunction that was not brought to the attention
of their healthcare providers; healthcare providers
may have misdiagnosed some individuals; or some
vaccine exposures may not have been appropri-
ately classified. While these limitations, possibly
present in the data examined in the current study,
should not have significantly impacted the results
observed, it is unclear how differential application
would have occurred to affect the study cohorts
examined, based upon the Thimerosal doses that
the individuals received. Moreover, misclassifica-
tion occurring in the data examined would tend
to bias any results observed toward the null
hypothesis, since such effects would result in indi-
viduals being placed in the wrong exposure and/or
outcome categories examined, and this would
result in decreased statistical power to determine
true potential exposure–outcome relationships.
In addition, another potential limitation of the
present study is that exposure to other sources of
Hg were not evaluated. The individuals examined
in the present study very likely incurred other
organic Hg exposure from other Thimerosal-
containing childhood vaccines, breastfeeding,
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amalgams, fish, or other environmental sources.
While these other sources of Hg may play a signifi-
cant involvement in the pathogenesis specific
delays in development, these Hg exposures, not
accounted for in this study, would actually tend
to bias the results observed toward the null hypoth-
esis because they potentially would confound the
specific exposure classifications of Hg examined.
For example, individuals classified as having lower
organic Hg exposure from Thimerosal-containing
vaccines may have actually received high doses of
Hg from other sources, and individuals having
higher organic Hg exposure from Thimerosal-
containing vaccines may have actually received
low doses of Hg from other sources, with the net
result tending to minimize the magnitude of the
associations observed.
Finally, the current study suffers from the
potential limitation that analyses were not con-
ducted to further explore the precise timing and
cumulative doses of organic-Hg from all
Thimerosal-containing childhood vaccines associ-
ated with maximum adverse consequences. In
future studies, it would be worthwhile to explore
these precise timing and cumulative-dose phenom-
ena. In addition, evaluating other neurodevelop-
mental outcomes, as well as other covariates
such as race, birth weight, gestational age, socioe-
conomic status, environmental conditions, as well
as any complications during pregnancy, etc., that
may affect the magnitude of the adverse effects
found, would be valuable.
6. Conclusion
The present study provides compelling new evi-
dence to confirm and extend previous epidemiolog-
ical studies finding a significant relationship
between organic Hg exposure from Thimerosal-
containing childhood vaccines and the subsequent
increased risk of a diagnosis for specific delays in
development. The present study employed a longi-
tudinal cohort study design that allowed for the
determination of the attributable risk of exposure
to organic Hg from T-HBVs administered within
the first 6 months of life. It was estimated that
during the approximately one decade when
T-HBVs were routinely recommended to all US
children, 0.5–1 million infants were diagnosed
with specific delays in development as a conse-
quence of hepatitis B vaccination-related Hg expo-
sure. Furthermore, in economic terms, the lifetime
societal cost of such individuals to the United
States may exceed $1 trillion. As a consequence,while routine childhood vaccination is an important
public health tool to reduce the morbidity and
mortality associated with infectious diseases, the
results of the present study raise fundamental and
potentially alarming questions about the adverse
health and economic impacts of recommendations
to routinely administer Thimerosal-containing child-
hood vaccines to infants worldwide.
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